Can you take Pexidartinib with Revuforj?
1 drug interaction and 13 additional warnings found for the following 2 drugs:
- pexidartinib
- Revuforj (revumenib)
Drug interactions
Major drug interactions
Major:
pexidartinib revumenib
Applies to: pexidartinib and Revuforj (revumenib)
Pexidartinib may significantly reduce the blood levels of revumenib, which may make the medication less effective in treating your cancer.
Using pexidartinib with revumenib may also increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening. You may be more susceptible if you have:
- a heart condition called congenital long QT syndrome
- other cardiac diseases
- conduction abnormalities
- electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting)
You should seek immediate medical attention if you experience sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications.
Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Major food/lifestyle interactions
Major:
pexidartinib Food/Lifestyle
Applies to: pexidartinib
You may experience reduced absorption of pexidartinib in the presence of food. Pexidartinib should be taken on an empty stomach at least 1 hour before or 2 hours after food. This will make it easier for your body to absorb the medication.
Also, while taking pexidartinib, you should avoid grapefruits and grapefruit juice. Grapefruit and grapefruit juice can raise the levels of pexidartinib in your body and lead to potentially dangerous adverse effects. Do not increase or decrease the amount of grapefruit products in your diet without first talking to your doctor.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Moderate food/lifestyle interactions
Moderate:
revumenib Food/Lifestyle
Applies to: Revuforj (revumenib)
High fat content meals may affect the absorption of revumenib. It is recommended that revumenib be taken while fasting or with a low fat meal (approximately 400 calories, with 25% of calories from fat).
Grapefruit juice may also increase the blood levels of revumenib which can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening.
You may be more susceptible if you have:
- a heart condition called congenital long QT syndrome
- other cardiac diseases
- conduction abnormalities
- electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting)
Increased levels of revumenib may also increase the risk of developing a serious and potentially life-threatening condition called differentiation syndrome.
Symptoms of differentiation syndrome include:
- fever
- cough
- shortness of breath
- severe headache
- confusion
- dizziness
- rapid weight gain
- swelling
- decreased urination
You should seek immediate medical attention if you develop any of these symptoms and/or symptoms of QT prolongation such as sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with revumenib.
The risk and/or severity of other side effects may also increase, including nausea, vomiting, diarrhea, fever or infections. You may need additional monitoring if grapefruit or grapefruit juice are consumed during treatment with revumenib.
Talk to a healthcare provider if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
11 potential interactions Applies to: 9 conditions, including Heart Failure, Arrhythmia, Hypokalemia, Liver Disease, and Long QT Syndrome.
Arrhythmia
Moderate:
Revuforj
The revumenib in Revuforj has a moderate potential interaction with Arrhythmia.
Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.
Bile Acid Synthesis Disorders
Major:
pexidartinib
Pexidartinib has a major potential interaction with Bile Acid Synthesis Disorders.
Pexidartinib can cause serious and potentially fatal liver injury. No dose adjustment is needed for patients with mild hepatic impairment. A dose reduction (125 mg twice a day) is recommended for patients with moderate hepatic impairment. Pexidartinib has not been studied in patients with severe hepatic impairment. Avoid this drug in patients with preexisting increased serum transaminases; total bilirubin or direct bilirubin (greater than ULN); or active liver or biliary tract disease, including increased alkaline phosphatase. It is recommended to monitor liver tests before initiation of treatment and at specified intervals during treatment. Withhold and reduce the dose or permanently discontinue pexidartinib based on the severity of hepatotoxicity.
Biliary Obstruction
Major:
pexidartinib
Pexidartinib has a major potential interaction with Biliary Obstruction.
Pexidartinib can cause serious and potentially fatal liver injury. No dose adjustment is needed for patients with mild hepatic impairment. A dose reduction (125 mg twice a day) is recommended for patients with moderate hepatic impairment. Pexidartinib has not been studied in patients with severe hepatic impairment. Avoid this drug in patients with preexisting increased serum transaminases; total bilirubin or direct bilirubin (greater than ULN); or active liver or biliary tract disease, including increased alkaline phosphatase. It is recommended to monitor liver tests before initiation of treatment and at specified intervals during treatment. Withhold and reduce the dose or permanently discontinue pexidartinib based on the severity of hepatotoxicity.
Heart Failure
Moderate:
Revuforj
The revumenib in Revuforj has a moderate potential interaction with Heart Failure.
Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.
Hypokalemia
Moderate:
Revuforj
The revumenib in Revuforj has a moderate potential interaction with Hypokalemia.
Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.
Liver Disease
Major:
pexidartinib
Pexidartinib has a major potential interaction with Liver Disease.
Pexidartinib can cause serious and potentially fatal liver injury. No dose adjustment is needed for patients with mild hepatic impairment. A dose reduction (125 mg twice a day) is recommended for patients with moderate hepatic impairment. Pexidartinib has not been studied in patients with severe hepatic impairment. Avoid this drug in patients with preexisting increased serum transaminases; total bilirubin or direct bilirubin (greater than ULN); or active liver or biliary tract disease, including increased alkaline phosphatase. It is recommended to monitor liver tests before initiation of treatment and at specified intervals during treatment. Withhold and reduce the dose or permanently discontinue pexidartinib based on the severity of hepatotoxicity.
Moderate:
Revuforj
The revumenib in Revuforj has a moderate potential interaction with Liver Disease.
Revumenib has not been studied in patients with severe liver or renal impairment.
Long QT Syndrome
Moderate:
Revuforj
The revumenib in Revuforj has a moderate potential interaction with Long QT Syndrome.
Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.
Magnesium Imbalance
Moderate:
Revuforj
The revumenib in Revuforj has a moderate potential interaction with Magnesium Imbalance.
Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.
Renal Dysfunction
Moderate:
pexidartinib
Pexidartinib has a moderate potential interaction with Renal Dysfunction.
Dose modification of pexidartinib is needed for patients with renal impairment. It is recommended to reduce the dose when administering pexidartinib to patients with mild to severe renal impairment (CrCl 15 to 89 mL/min, estimated by Cockcroft-Gault using actual body weight). The recommended dosage is 125 mg in the morning and 250 mg in the evening with a low-fat meal.
Moderate:
Revuforj
The revumenib in Revuforj has a moderate potential interaction with Renal Dysfunction.
Revumenib has not been studied in patients with severe liver or renal impairment.
Report options
More resources
pexidartinib
A total of 689 drugs are known to interact with pexidartinib.
- Pexidartinib is in the drug class multikinase inhibitors.
- Pexidartinib is used to treat the following conditions:
Revuforj
A total of 583 drugs are known to interact with Revuforj.
- Revuforj is in the drug class miscellaneous antineoplastics.
- Revuforj is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.